HUP0401481A2 - Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401481A2
HUP0401481A2 HU0401481A HUP0401481A HUP0401481A2 HU P0401481 A2 HUP0401481 A2 HU P0401481A2 HU 0401481 A HU0401481 A HU 0401481A HU P0401481 A HUP0401481 A HU P0401481A HU P0401481 A2 HUP0401481 A2 HU P0401481A2
Authority
HU
Hungary
Prior art keywords
methyl
pyrrolidin
quinolin
benzonitrile
alkyl
Prior art date
Application number
HU0401481A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael G. Klug
Patrizio Mattei
Werner Müller
Werner Neidhart
Matthias Heinrich Nettekoven
Philippe Pflieger
Jean-Marc Plancher
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of HUP0401481A2 publication Critical patent/HUP0401481A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0401481A 2001-09-28 2002-09-20 Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények HUP0401481A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123496 2001-09-28
PCT/EP2002/010618 WO2003028726A1 (en) 2001-09-28 2002-09-20 Quinoline derivatives as neuropeptide y antagonists

Publications (1)

Publication Number Publication Date
HUP0401481A2 true HUP0401481A2 (hu) 2004-12-28

Family

ID=8178804

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401481A HUP0401481A2 (hu) 2001-09-28 2002-09-20 Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Country Status (23)

Country Link
US (4) US6787558B2 (enExample)
EP (1) EP1432421A1 (enExample)
JP (1) JP4187652B2 (enExample)
KR (1) KR100605765B1 (enExample)
CN (1) CN1289087C (enExample)
AR (1) AR040626A1 (enExample)
AU (1) AU2002342735B2 (enExample)
BR (1) BR0212929A (enExample)
CA (1) CA2460865C (enExample)
GT (1) GT200200197A (enExample)
HR (1) HRP20040272A2 (enExample)
HU (1) HUP0401481A2 (enExample)
IL (1) IL160750A0 (enExample)
MX (1) MXPA04002825A (enExample)
NO (1) NO20041235L (enExample)
NZ (1) NZ531517A (enExample)
PA (1) PA8555401A1 (enExample)
PE (1) PE20030603A1 (enExample)
PL (1) PL370414A1 (enExample)
RU (1) RU2300531C2 (enExample)
UY (1) UY27462A1 (enExample)
WO (1) WO2003028726A1 (enExample)
ZA (1) ZA200402359B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US8759348B2 (en) * 2007-05-17 2014-06-24 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009097278A1 (en) * 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9212144B2 (en) * 2014-01-10 2015-12-15 Northwestern University 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
US9663468B2 (en) 2014-01-10 2017-05-30 Northwestern University 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
DK3452465T3 (da) * 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP7575952B2 (ja) 2019-01-08 2024-10-30 杏林製薬株式会社 15-pgdh阻害薬
WO2020160151A1 (en) * 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
EP3966208A4 (en) * 2019-05-10 2024-01-03 Antidote IP Holdings, LLC COMPOUNDS AND METHODS FOR TREATING CANCER

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
JPH068292B2 (ja) * 1985-05-07 1994-02-02 アルカロイダ ベギエスゼティ ギャル トリアゾリルキノリン誘導体
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AU719392B2 (en) 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
US6199042B1 (en) * 1998-06-19 2001-03-06 L&H Applications Usa, Inc. Reading system
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
FR2795726A1 (fr) * 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
AU7738000A (en) 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists

Also Published As

Publication number Publication date
US20030158179A1 (en) 2003-08-21
IL160750A0 (en) 2004-08-31
RU2004113207A (ru) 2005-05-27
US7166589B2 (en) 2007-01-23
GT200200197A (es) 2003-06-19
HK1074176A1 (en) 2005-11-04
US20060148794A1 (en) 2006-07-06
US7064134B2 (en) 2006-06-20
UY27462A1 (es) 2003-04-30
KR20040039442A (ko) 2004-05-10
PE20030603A1 (es) 2003-07-12
NZ531517A (en) 2005-11-25
JP2005508923A (ja) 2005-04-07
AU2002342735B2 (en) 2005-09-22
US20040259858A1 (en) 2004-12-23
EP1432421A1 (en) 2004-06-30
KR100605765B1 (ko) 2006-07-31
US7012073B2 (en) 2006-03-14
US20060063758A1 (en) 2006-03-23
JP4187652B2 (ja) 2008-11-26
CA2460865A1 (en) 2003-04-10
WO2003028726A1 (en) 2003-04-10
CN1607951A (zh) 2005-04-20
NO20041235L (no) 2004-03-24
PL370414A1 (en) 2005-05-30
ZA200402359B (en) 2005-05-03
US6787558B2 (en) 2004-09-07
HRP20040272A2 (en) 2004-08-31
BR0212929A (pt) 2004-10-13
PA8555401A1 (es) 2003-07-28
MXPA04002825A (es) 2004-07-02
CN1289087C (zh) 2006-12-13
RU2300531C2 (ru) 2007-06-10
AR040626A1 (es) 2005-04-13
CA2460865C (en) 2008-09-09

Similar Documents

Publication Publication Date Title
BR0009007A (pt) Derivados de piperidina, tetraidropiridina epiperazina; composto; composição farmacêutica;utilização e método
EA200601192A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА
MX2010005753A (es) Derivados de isoxazolo-pirazina.
ATE517882T1 (de) Chinolinderivate
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
SE0402735D0 (sv) Novel compounds
NZ527081A (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
CY1109890T1 (el) ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
MX2009006921A (es) Derivados azaespiro.
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
MXPA05009574A (es) Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas.
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
EA200970455A1 (ru) ЗАМЕЩЕННЫЙ 8-ПИПЕРИДИНИЛ-2-ПИРИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОН И ПРОИЗВОДНЫЕ 8-ПИПЕРИДИНИЛ-2-ПИРИМИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА
HUP0303751A2 (hu) N-fenil-pirimidin-amin-származékok alkalmazása hízósejt alapú betegségekhez hasonló allergiás rendellenességek kezelésére alkalmas gyógyszerkészítmények előállítására
MX2009005507A (es) Derivados de espiro-piperidina.
WO2008077810A3 (en) Spiro-piperidine derivatives
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
WO2002085853A3 (en) Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
NO20072165L (no) Metabolitter av visse (1,4)diazepino(6,7,1-IJ)kinolinderivater og fremgangsmater for fremstilling og anvendelse derav
HUP0401350A2 (hu) Terápiás hatású új imidazopiridin-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees